Marlen Haderlein1, Sebastian Lettmaier2, Melanie Langheinrich3, Axel Schmid4, Sabine Semrau2, Markus Hecht2, Michael Beck5, Daniela Schmidt5, Robert Grützmann3, Rainer Fietkau2, Axel Denz3. 1. Department of Radiation Oncology, University Hospital of Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. marlen.haderlein@uk-erlangen.de. 2. Department of Radiation Oncology, University Hospital of Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. 3. Department of Surgery, University Hospital of Erlangen, Erlangen, Germany. 4. Department of Radiology, University Hospital of Erlangen, Erlangen, Germany. 5. Department of Nuclear Medicine, University Hospital of Erlangen, Erlangen, Germany.
Abstract
PURPOSE: The aim was to evaluate the outcome of treatment-naive patients with synchronous metastatic rectal cancer after chemotherapy with FOLFOXIRI followed by local therapeutic procedures of all tumor lesions as complete as possible. METHODS: We reviewed data of 30 patients with synchronous distant metastatic rectal cancer who underwent chemotherapy with FOLFOXIRI and subsequent local therapy in our institution. RESULTS: Median follow-up was 28 months (range: 8; 74). Cumulative overall survival (OS) and progression-free survival (PFS) was 93.3, 76.9, 55.6% and 46.2, 29.7, 29.7% after 1, 2, 4 years. Non-response to chemotherapy with FOLFOXIRI was associated with a highly significant decreased OS (p < 0.0001). The consistent use of local ablative procedures led to a statistically significant increase in OS (p < 0.0001), but not in PFS (p = 0.635). Patients with ≤ 4 distant metastases showed a better OS (p = 0.033). CONCLUSIONS: Response to intensified first-line chemotherapy with FOLFOXIRI, treatment of the primary rectal tumor, and repeated thorough local ablative procedures in patients with synchronous metastasized rectal cancer may lead to long-term survival, even in a subset of patients with unresectable disease at initial diagnosis.
PURPOSE: The aim was to evaluate the outcome of treatment-naive patients with synchronous metastatic rectal cancer after chemotherapy with FOLFOXIRI followed by local therapeutic procedures of all tumor lesions as complete as possible. METHODS: We reviewed data of 30 patients with synchronous distant metastatic rectal cancer who underwent chemotherapy with FOLFOXIRI and subsequent local therapy in our institution. RESULTS: Median follow-up was 28 months (range: 8; 74). Cumulative overall survival (OS) and progression-free survival (PFS) was 93.3, 76.9, 55.6% and 46.2, 29.7, 29.7% after 1, 2, 4 years. Non-response to chemotherapy with FOLFOXIRI was associated with a highly significant decreased OS (p < 0.0001). The consistent use of local ablative procedures led to a statistically significant increase in OS (p < 0.0001), but not in PFS (p = 0.635). Patients with ≤ 4 distant metastases showed a better OS (p = 0.033). CONCLUSIONS: Response to intensified first-line chemotherapy with FOLFOXIRI, treatment of the primary rectal tumor, and repeated thorough local ablative procedures in patients with synchronous metastasized rectal cancer may lead to long-term survival, even in a subset of patients with unresectable disease at initial diagnosis.
Entities:
Keywords:
FOLFOXIRI; Local ablative procedures; Rectal cancer; Synchronous distant metastases
Authors: T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger Journal: Ann Oncol Date: 2012-03-19 Impact factor: 32.976
Authors: A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol Journal: Br J Radiol Date: 2010-12-15 Impact factor: 3.039
Authors: Konrad Mohnike; Steffen Wolf; Robert Damm; Max Seidensticker; Ricarda Seidensticker; Frank Fischbach; Nils Peters; Peter Hass; Günther Gademann; Maciej Pech; Jens Ricke Journal: Strahlenther Onkol Date: 2016-02-29 Impact factor: 3.621
Authors: Sulaiman Nanji; Safiya Karim; Ephraim Tang; Kelly Brennan; Anna McGuire; C S Pramesh; Christopher M Booth Journal: Ann Thorac Surg Date: 2018-03-05 Impact factor: 4.330
Authors: K T Liu; J F Wan; J Zhu; G C Li; W J Sun; L J Shen; S J Cai; W L Gu; P Lian; Z Zhang Journal: Cancer Radiother Date: 2016-10-21 Impact factor: 1.018
Authors: Croix C Fossum; Jasim Y Alabbad; Lindsay B Romak; Christopher L Hallemeier; Michael G Haddock; Marianne Huebner; Eric J Dozois; David W Larson Journal: J Gastrointest Oncol Date: 2017-08
Authors: T Gruenberger; J Bridgewater; I Chau; P García Alfonso; M Rivoire; S Mudan; S Lasserre; F Hermann; D Waterkamp; R Adam Journal: Ann Oncol Date: 2014-12-23 Impact factor: 32.976